Working with mice, hamsters, and nonhuman primates, Penn researchers found that a modified version of the mRNA COVID-19 ...

The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Repeated mRNA vaccinations boost mucosal antibodies, improving defense against COVID-19. This may help enhance protection ...

Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating on October 28. Joseph Stringer has ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

Like humans and other complex multicellular organisms, single-celled bacteria can fall ill and fight off viral infections. A ...

A new hydrophobic tag enables the high-purity production of a key intermediate in the chemical synthesis of capped mRNA and ...

Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older – ...

Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in ...